Company** Product Description Indication Type Action/Date

Name

CANCER

Aeterna Neovastat Shark cartilage extract Refractory lung and Presented results of

Laboratories Inc. (AE-941) with anti-angiogenic prostate cancer Phase I trial (conducted in

(TSE:AEL; Canada) and anti-inflammatory Canada and U.S.) at Euro-

properties pean Association for

Cancer Research meeting

in Stockholm (8/20)

Biomira Inc. BLP25 Synthetic MUC-1 Non-small cell Initiated Phase I trial in

(Canada) therapeutic vaccine; lung cancer Canada (8/5)

consists of 25 amino

acid sequence of the

MUC-1 cancer mucin,

encapsulated in lipo-

somes; suppresses

tumor angiogenesis

Chiron Corp. and Proleukin Aldesleukin; recombi- Metastatic renal cell Approved for marketing

Hyup Jin Corp. nant human interleu- carcinoma in South Korea (8/12)

(South Korea) kin-2

CARDIOVASCULAR

Inex Pharma- INX-3280 Antisense compound Cardiovascular resten- Presented results of

ceuticals Corp. that blocks function of osis (administered via Phase II trial (conducted

(TSE:IEX; Canada) and c-myc gene (bolus local delivery catheter in the Netherlands) at

Schwarz Pharma injection) directly into coronary 20th Annual Congress

AG (Germany) artery) of the European Society

of Cardiology in Vienna,

Austria (8/24)

DIABETES

Amylin Pharma- AC2993 Exendin-4; synthetic Type II diabetes Initiated Phase I trial in

ceuticals Inc. version of protein U.K. (8/18)

originally isolated from

saliva of Gila monster;

(has 50% structural

homology with human

hormone glucagon-

like peptide-1)

INFECTION

Agouron Pharma- Viracept Nelfinavir mesylate; HIV infection and Approved for marketing

ceuticals Inc. HIV protease inhibitor AIDS in adults and in Canada (8/12)

(synthetic small children; combination

molecule) therapy with reverse

transcriptase inhibitors

BioChem Pharma Zeffix Lamivudine; nucleoside Chronic hepatitis B Approved for marketing

Inc. (Canada) and analogue (oral) virus infection in the Philippines (8/20)

Glaxo Wellcome

plc (NYSE:LX; U.K.)

The Immune Remune Envelope-depleted HIV infection and Results of open-label

Response Corp inactivated AIDS virus AIDS trial conducted in Thai-

and Agouron (emulsified with land (60-week follow-up)

Pharmaceuticals adjuvant) published in Vol. 12 1998

Inc. issue of AIDS (8/25)

MedImmune Inc. Synagis Palivizumab; human- Prevention of serious Submitted marketing

and Abbott Labor- ized monoclonal anti- RSV disease in certain authorization application

atories (NYSE:ABT) body to respiratory high-risk infants and in the European Union

syncytial virus (RSV); children (causes pneu- (8/11)

binds to fusion protein monia, bronchiolitis)

on viral surface (intra-

muscular injection)

NeXstar Pharma- AmBisome Liposomal formulation Empirical treatment of U.K.'s Medicines Control

ceuticals Inc. of amphotericin B presumed fungal infec- Agency approved ex-

tions in febrile neutro- panded label (new

penic patients indication) (8/18)

SciClone Pharma- Zadaxin Synthetic version of Chronic hepatitis C Approved for marketing

ceuticals Inc. (thymosin naturally occurring pep- virus infection in the Philippines (8/27)

alpha 1) tide hormone thymosin

(immunomodulator)

SciClone Pharma- Zadaxin Synthetic version of Chronic hepatitis B Approved for marketing

ceuticals Inc. (thymosin naturally occurring pep- virus infection in Myanmar (formerly

alpha 1) tide hormone thymosin Burma) (8/27)

(immunomodulator)

SciClone Pharma- Zadaxin Synthetic version of Chronic hepatitis B Filed marketing applica-

ceuticals Inc. (thymosin naturally occurring pep- virus infection tions in Laos and Taiwan

alpha 1) tide hormone thymosin (8/27)

(immunomodulator)

Synsorb Biotech Synsorb Pk Orally delivered carbo- Co-administration with Takeda said that its clin-

Inc. (Canada) and hydrate attached to inert, antibiotics to treat child- ical study in Japan has

Takeda Chemical insoluble support; binds ren infected with vero- been completed (8/18)

Ltd. (Japan) to toxins secreted by toxigenic Escherichia

bacteria in the gastro- coli

intestinal tract

MISCELLANEOUS

Hemispherx Bio- Ampligen Double-stranded syn- Chronic fatigue Submitted marketing

Pharma Inc. thetic RNA compound syndrome/myalgic application in European

(AMEX:HEB) poly I:poly C12U encephalomyelitis Union (8/18)

Hyal Pharma- Solarase 3% diclofenac gel Actinic keratosis Australian Drug Evalua-

ceutical Corp. (topical) (precancerous skin tion Committee did not

(TSE:HPC; Canada) lesions caused by approve product market-

exposure to sun) ing application (8/12)

NOTES:

This chart is intended to provide a monthly update on the clinical and regulatory status of biotech and biotech-related products in development in countries other than the U.S., whether those products are being developed by U.S.-based or non-U.S.-based firms. It covers events that were announced in August 1998. It does not cover ongoing clinical trials for which no news was issued in that month.

** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 11-12.

No Comments